Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells

Oncotarget

Volumn 6, Issue 32, 2015, Pages 32426-32438

  Yu, Zhe ^a,b   Tan, Zhiwu ^a   Lee, Boon Kiat ^a   Tang, Jiansong ^a   Wu, Xilin ^a   Cheung, Ka Wai ^a   Lo, Nathan Tin Lok ^a   Man, Kwan ^a   Liu, Li ^a   Chen, Zhiwei ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antigen spreading; CD8+T cells; Immune response; Immunity; Immunology and Microbiology Section; MDSCs; Mesothelioma; Vaccination

Indexed keywords

ANTIGEN P24; CD8 ANTIGEN; DNA VACCINE; IMMUNOGLOBULIN G ANTIBODY; MEMBRANE PROTEIN; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN TIM 3; UNCLASSIFIED DRUG; CANCER VACCINE; GAG PROTEIN; HAVCR2 PROTEIN, HUMAN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; PDCD1 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL PROTECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DOSE RESPONSE; FEMALE; IMMUNOSTIMULATION; IN VIVO STUDY; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; POLYMORPHONUCLEAR CELL; PROTEIN FUNCTION; SUPPRESSOR CELL; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; COCULTURE; CYTOTOXICITY; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOLOGY; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MESOTHELIOMA; METABOLISM; PATHOLOGY; SCID MOUSE; TIME FACTOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; CANCER VACCINES; CELL LINE; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HIV CORE PROTEIN P24; HIV-1; IMMUNIZATION; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE PROTEINS; MESOTHELIOMA; MICE, INBRED BALB C; MICE, SCID; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TRANSFECTION; TUMOR ESCAPE; VACCINES, DNA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946031852     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5856     Document Type: Article

References (39)

1. Vanneman M and DranoffG. Combining immunotherapy and targeted therapies in cancer treatment. Nature reviews Cancer. 2012; 12:237-251.
2. Restifo NP, Dudley ME and Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nature reviews Immunology. 2012; 12:269-281.
3. Coulie PG, Van den Eynde BJ, van der Bruggen P and Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nature reviews Cancer. 2014; 14:135-146.
4. Barry M and Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. Nature reviews Immunology. 2002; 2:401-409.
5. Tan Z, Zhou J, Cheung AK, Yu Z, Cheung KW, Liang J, Wang H, Lee BK, Man K, Liu L, Yuen KY and Chen Z. Vaccine-elicited CD8+ T cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment. Cancer research. 2014; 74:6010-21.
6. Zhou JY, Cheung AKL, Tan ZW, Wang HB, Yu WB, Du YH, Kang YX, Lu XF, Liu L, Yuen KY and Chen ZW. PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8(+) T cells in mice. J Clin Invest. 2013; 123:2629-2642.
7. Zhu Y, Ju S, Chen E, Dai S, Li C, Morel P, Liu L, Zhang X and Lu B. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses. Journal of immunology. 2010; 185:3174-3183.
8. Lu T, Ramakrishnan R, Altiok S, Youn JI, Cheng P, Celis E, Pisarev V, Sherman S, Sporn MB and Gabrilovich D. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest. 2011; 121:4015-4029.
9. Lindau D, Gielen P, Kroesen M, Wesseling P and Adema GJ. The immunosuppressive tumour network: myeloidderived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013; 138:105-115.
10. Gabrilovich DI and Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology. 2009; 9:162-174.
11. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM and Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15:5323-5337.
12. Khaled YS, Ammori BJ and Elkord E. Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol. 2013; 91:493-502.
13. Gabrilovich DI, Ostrand-Rosenberg S and Bronte V. Coordinated regulation of myeloid cells by tumours. Nature reviews Immunology. 2012; 12:253-268.
14. Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J, Boegel S, Schrors B, Vascotto F, Castle JC, Tadmor AD, Schoenberger SP, Huber C, Tureci O and Sahin U. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015; 520:692-696.
15. Buckwalter MR and Srivastava PK. Mechanism of dichotomy between CD8+ responses elicited by apoptotic and necrotic cells. Cancer immunity. 2013; 13:2.
16. Storkus WJ and Falo LD, Jr. A 'good death' for tumor immunology. Nature medicine. 2007; 13:28-30.
17. Zhou J, Cheung AK, Liu H, Tan Z, Tang X, Kang Y, Du Y, Wang H, Liu L and Chen Z. Potentiating functional antigenspecific CD8(+) T cell immunity by a novel PD1 isoformbased fusion DNA vaccine. Molecular therapy: the journal of the American Society of Gene Therapy. 2013; 21:1445-1455.
18. Inoue H and Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell death and differentiation. 2014; 21:39-49.
19. Scott AM, Wolchok JD and Old LJ. Antibody therapy of cancer. Nature reviews Cancer. 2012; 12(4):278-287.
20. Schreiber H, Ward PL, Rowley DA and Stauss HJ. Unique tumor-specific antigens. Annual review of immunology. 1988; 6:465-483.
21. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, van Veelen P, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. The Journal of experimental medicine. 2006; 203:1259-1271.
22. Corbiere V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethe B, van Baren N, Van den Eynde BJ, Boon T and Coulie PG. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer research. 2011; 71:1253-1262.
23. Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E, Finnberg N, El-Deiry WS, Winograd R, Vonderheide RH, English NR, Knight SC, Yagita H, McCaffrey JC, Antonia S, Hockstein N, Witt R, et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-Rmediated apoptosis. J Clin Invest. 2014; 124:2626-2639.
24. Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA and Ostrand-Rosenberg S. Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood. 2011; 117:5381-5390.
25. Drake CG, Jaffee E and Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006; 90:51-81.
26. Poschke I, Mougiakakos D and Kiessling R. Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immun. 2011; 60:1161-1171.
27. Whiteside TL, Mandapathil M, Szczepanski M and Szajnik M. Mechanisms of tumor escape from the immune system: Adenosine-producing Treg, exosomes and tumor-associated TLRs. B Cancer. 2011; 98:E25-E31.
28. Pulido J, Kottke T, Thompson J, Galivo F, Wongthida P, Diaz RM, Rommelfanger D, Ilett E, Pease L, Pandha H, Harrington K, Selby P, Melcher A and Vile R. Using virally expressed melanoma cDNA libraries to identify tumorassociated antigens that cure melanoma. Nat Biotechnol. 2012; 30:336-343.
29. Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P, Diaz RM, Chong H, Ilett E, Chester J, Pandha H, Harrington K, Selby P, Melcher A and Vile R. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nature medicine. 2011; 17:854-U223.
30. Finn OJ. Cancer vaccines: Between the idea and the reality. Nature Reviews Immunology. 2003; 3:630-641.
31. Vanderlugt CL and Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nature reviews Immunology. 2002; 2:85-95.
32. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL and Schiffman K. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol. 2002; 20:2624-2632.
33. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, ElashoffRM, McBride WH, Mukherji B, Cochran AJ, Glaspy JA and Economou JS. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003; 9:998-1008.
34. Tagawa M, Tada Y, Shimada H and Hiroshima K. Gene therapy for malignant mesothelioma: current prospects and challenges. Cancer gene therapy. 2013; 20:150-156.
35. Zhong S, Malecek K, Johnson LA, Yu Z, Vega-Saenz de Miera E, Darvishian F, McGary K, Huang K, Boyer J, Corse E, Shao Y, Rosenberg SA, Restifo NP, Osman I and Krogsgaard M. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:6973-6978.
36. Neveu B, Debeaupuis E, Echasserieau K, le MoullacVaidye B, Gassin M, Jegou L, Decalf J, Albert M, Ferry N, Gournay J, Houssaint E, Bonneville M and Saulquin X. Selection of high-avidity CD8 T cells correlates with control of hepatitis C virus infection. Hepatology. 2008; 48:713-722.
37. Weiss JM, Subleski JJ, Back T, Chen X, Watkins SK, Yagita H, Sayers TJ, Murphy WJ and Wiltrout RH. Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/alphaCD40 therapy. J Immunol. 2014; 192:5821-5829.
38. Chuang CM, Monie A, Wu A, Pai SI and Hung CF. Combination of viral oncolysis and tumor-specific immunity to control established tumors. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15:4581-4588.
39. Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Baccarini S, Maccari S, Ramoni C, Belardelli F and Proietti E. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clinical Cancer Research. 2007; 13:644-653.